


글로벌 제약사 파이프라인 분석

- BMS -

2022. 10.

국가신약개발사업단


• 질환별 파이프라인



 Bristol Myers Squibb

질환분야	개수	비중
Oncology	58	41%
Hematology	47	33%
Immunology	22	15%
Cardiovascular	10	7%
Neuroscience	4	3%
Metabolic	1	1%
Infectious	1	1%
합계	143개	100%

- 물질별 파이프라인



 Bristol Myers Squibb

물질	개수	비중
Antibody	67	47%
Small molecules	50	35%
Cell Therapy	13	9%
N/A(Not Applicable)	6	4%
Protein	4	3%
ADC	2	1%
RNA	1	1%
합계	143개	100%

• 상세 파이프라인

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
1	Cardiovascular	Phase 3	SAR439152	Camzyos	mavacamten	Obstructive hypertrophic cardio myopathy septal reduction therapy eligible	Small molecules	Myosin	Myosin inhibitor	Mono	-
2	Cardiovascular	Phase 2	BMS-562247-01	Eliquis	apixaban	Heart disease, pediatrics	Small molecules	FXα	FXα inhibitor	Mono	-
3	Cardiovascular	Phase 2	BMS-986177		milvexian	Venous Thrombotic disorders prevention	Small molecules	FXIα	FXIα inhibitor	Mono	-
4	Cardiovascular	Phase 2	BMS-986177		milvexian	Secondary stroke prevention	Small molecules	FXIα	FXIα inhibitor	Mono	-
5	Cardiovascular	Phase 2	SAR439152	Camzyos	mavacamten	Non-obstructive hypertrophic cardiomyopathy	Small molecules	Myosin	Myosin inhibitor	Mono	-
6	Cardiovascular	Phase 2	SAR439152	Camzyos	mavacamten	Heart failure with preserved ejection fraction	Small molecules	Myosin	Myosin inhibitor	Mono	-
7	Cardiovascular	Phase 2	SAR440181		danicamtiv	Genetic dilated cardiomyopathy	Small molecules	Myosin	Myosin activator	Mono	-
8	Cardiovascular	Phase 1			Cardiac Myosin inhibitor	Hypertrophic cardiomyopathy	Small molecules	Myosin	Myosin inhibitor	Mono	-
9	Cardiovascular	Phase 1			FXIα inhibitor	Thrombotic disorders	Small molecules	FXIα	FXIα inhibitor	Mono	-
10	Cardiovascular	Phase 1			ROMK inhibitor	Heart failure	Small molecules	ROMK	ROMK inhibitor	Mono	-
11	Hematology	Phase 3	ACE-536	Reblozyl	luspatercept-aamt	Myelodysplastic syndromes, ESA naive	Protein	GDF8, GDF11	GDF8, GDF11 inhibitor	Mono	Acceleron

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
12	Hematology	Phase 3	ACE-536	Reblozyl	luspatercept-aamt	Beta-thalassemia, non-transfusion-dependent	Protein	GDF8, GDF11	GDF8, GDF11 inhibitor	Mono	Acceleron
13	Hematology	Phase 3	ACE-536	Reblozyl	luspatercept-aamt	Myelofibrosis anemia	Protein	GDF8, GDF11	GDF8, GDF11 inhibitor	Mono	Acceleron
14	Hematology	Phase 3	AG-221	Idhifa	enasidenib	Acute myeloid leukemia, relapsed/refractory	Small molecules	IDH2	IDH2 inhibitor	Mono	Agios, Avencell
15	Hematology	Phase 3	BMS-936558	Opdivo	nivolumab	Hodgkin lymphoma, refractory	Antibody	PD-1	PD-1 antagonist	Mono	Ono
16	Hematology	Phase 3	CC-486	Onureg	azacitidine	Myelodysplastic syndromes, lower risk	Small molecules	DNA methyltransferase	DNA methyltransferase inhibitor	Mono	-
17	Hematology	Phase 3	CC-486	Onureg	azacitidine	Angioimmunoblastic T-cell lymphoma	Small molecules	DNA methyltransferase	DNA methyltransferase inhibitor	Mono	-
18	Hematology	Phase 3	FK228	Istodax	romidepsin	Peripheral T-cell lymphoma, 1L	Small molecules	HDAC	HDAC inhibitor	Mono	-
19	Hematology	Phase 3	JCAR017	Breyanzi	liso-cel	Large B-cell lymphoma, 2L	Cell Therapy	CD19	CD19 CAR-T	Mono	-
20	Hematology	Phase 3		Empliciti+ Revlimid	elotuzumab+ lenalidomide	Multiple myeloma, 1L	Antibody	SLAMF7;CRBN	Cytotoxic to cells expressing SLAMF7; CRBN activator	Combination	Abbvie
21	Hematology	Phase 3		Inrebic	fedratinib	Myelofibrosis, previously treated with Ruxolitinib	Small molecules	JAK-2	JAK-2 inhibitor	Mono	Sanofi
22	Hematology	Phase 3		Abecma	ide-cel	Multiple myeloma, relapsed/refractory, 3L	Cell Therapy	BCMA	BCMA CAR-T	Mono	Bluebird bio
23	Hematology	Phase 2	AG-221	Idhifa	enasidenib	Acute myeloid leukemia, 1L	Small molecules	IDH2	IDH2 inhibitor	Mono	Agios, Avencell

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
24	Hematology	Phase 2	BMS-936558	Opdivo	nivolumab	Primary testicular lymphoma	Antibody	PD-1	PD-1 antagonist	Mono	-
25	Hematology	Phase 2	BMS-986158			Hematologic malignancies	Small molecules	BET	BET inhibitor	Mono	-
26	Hematology	Phase 2	CC-220		iberdomide	Multiple myeloma, relapsed/refractory	Small molecules	CRBN	CRBN activator	Mono	-
27	Hematology	Phase 2	CC-92480		CELMoD	Multiple myeloma, relapsed/refractory	Small molecules	CRBN	CRBN activator	Mono	-
28	Hematology	Phase 2	CC-99282		CELMoD	Non-Hodgkin lymphoma, relapsed/refractory	Small molecules	CRBN	CRBN activator	Mono	-
29	Hematology	Phase 2	JCAR017	Breyanzi	liso-cel	Chronic lymphocytic leukemia, 3L	Cell Therapy	CD19	CAR-T	Mono	-
30	Hematology	Phase 2	JCAR017	Breyanzi	liso-cel	Marginal zone lymphoma, 3L	Cell Therapy	CD19	CAR-T	Mono	-
31	Hematology	Phase 2	JCAR017	Breyanzi	liso-cel	Mantle cell lymphoma, 3L	Cell Therapy	CD19	CAR-T	Mono	-
32	Hematology	Phase 2	JCAR017	Breyanzi	liso-cel	Follicular lymphoma, 3L	Cell Therapy	CD19	CAR-T	Mono	-
33	Hematology	Phase 2		Abecma	ide-cel	Multiple myeloma, relapsed/refractory, 2L	Cell Therapy	BCMA	BCMA CAR-T	Mono	-
34	Hematology	Phase 2		Abecma	ide-cel	Multiple myeloma, relapsed/refractory, 4L	Cell Therapy	BCMA	BCMA CAR-T	Mono	-
35	Hematology	Phase 2		Abecma	ide-cel	Multiple myeloma, high-risk newly-diagnosed	Cell Therapy	BCMA	BCMA CAR-T	Mono	-
36	Hematology	Phase 2		Opdivo+ empliciti	nivolumab+ elotuzumab	Multiple myeloma, relapsed/refractory	Antibody	PD-1	PD-1 antagonist	Combination	Ono

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
37	Hematology	Phase 2				Large B-cell Lymphoma, transplant non-eligible, 2L	N/A	N/A	N/A	Mono	-
38	Hematology	Phase 2				B-Cell acute lymphoblastic leukemia, pediatrics, 2L	N/A	N/A	N/A	Mono	-
39	Hematology	Phase 2				C-cell lymphoma, high grade, 1L	N/A	N/A	N/A	Mono	-
40	Hematology	Phase 2				Hodgkin lymphoma, pediatrics	N/A	N/A	N/A	Mono	-
41	Hematology	Phase 1	BMS-936558	Opdivo	nivolumab	Hematologic malignancies	Antibody	PD-1	PD-1 antagonist	Mono	Ono
42	Hematology	Phase 1	BMS-986016	Opdualag	nivolumab+ relatlimab	Hematologic malignancies	Antibody	PD-1, LAG3	PD-1 antagonist, LAG inhibitor	Mono	Ono
43	Hematology	Phase 1	CC-220		iberdomide	Diffuse large B-cell lymphoma, 1L	Small molecules	N/A	N/A	Mono	-
44	Hematology	Phase 1	CC-220		iberdomide	Non-Hodgkin lymphoma	Small molecules	CRBN	CRBN activator	Mono	-
45	Hematology	Phase 1	CC-90009		GSPT1 CELMoD	Acute Myeloid Leukemia, relapsed/refractory	Small molecules	N/A	N/A	Mono	-
46	Hematology	Phase 1	CC-90010			Hematologic malignancies	Small molecules	BET	BET inhibitor	Mono	-
47	Hematology	Phase 1	CC-93269		alnuctamab BCMA TCE	Multiple myeloma, relapsed/refractory	Antibody	N/A	T-cell engager	Mono	-
48	Hematology	Phase 1	CC-98633		BCMA NEX T	Multiple myeloma, relapsed/refractory	Cell Therapy	N/A	N/A	Mono	-
49	Hematology	Phase 1	CC-99712		BCMA ADC	Multiple myeloma, relapsed/refractory	ADC	BCMA	N/A	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
50	Hematology	Phase 1			Anti-SIRPα	Hematologic malignancies	Antibody	SIRPα	N/A	Mono	-
51	Hematology	Phase 1			BCMA NKE	Multiple myeloma, relapsed/refractory	Antibody	N/A	NK cell engager	Mono	-
52	Hematology	Phase 1			CD33 NKE	Multiple myeloma, relapsed/refractory	Antibody	N/A	NK cell engager	Mono	-
53	Hematology	Phase 1			CD47xCD20	Non-Hodgkin lymphoma	Antibody	N/A	Bispecific antibody (CD47, CD20)	Mono	-
54	Hematology	Phase 1			CK1α degrader	Hematologic malignancies	N/A	CK1α	CK1α degrader	Mono	-
55	Hematology	Phase 1			GPRC5D CAR T	Multiple myeloma, relapsed/refractory	Cell Therapy	N/A	CAR-T	Mono	-
56	Hematology	Phase 1			ROR1 CAR T	Hematologic malignancies	Cell Therapy	ROR1	CAR-T	Mono	-
57	Hematology	Phase 1			CD19 NEX T	Non-Hodgkin lymphoma, relapsed/refractory	Cell Therapy	N/A	N/A	Mono	-
58	Immunology	Phase 3	BMS-986165		deucravacitinib	Psoriasis	Small molecules	TYK2	TYK2 inhibitor	Mono	-
59	Immunology	Phase 3	BMS-986165		deucravacitinib	Psoriatic arthritis	Small molecules	TYK2	TYK2 inhibitor	Mono	-
60	Immunology	Phase 3	RPC1063	Zeposia	ozanimod	Crohn's disease	Small molecules	S1P1, S1P5	S1P receptor modulator	Mono	-
61	Immunology	Phase 3	RPC4046		cendakimab	Eosinophilic esophagitis	Antibody	IL-13	IL-13 inhibitor	Mono	Abbvie
62	Immunology	Phase 2	BMS-986104		S1PR1 modulator	Atopic dermatitis	Small molecules	S1PR1	S1PR1 modulator	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
63	Immunology	Phase 2	BMS-986115		branebrutinib	Rheumatoid arthritis	Small molecules	gamma secretase	gamma secretase inhibitor	Mono	-
64	Immunology	Phase 2	BMS-986115		branebrutinib	Systemic lupus erythematosus	Small molecules	gamma secretase	gamma secretase inhibitor	Mono	-
65	Immunology	Phase 2	BMS-986115		branebrutinib	Sjogren's syndorome	Small molecules	gamma secretase	gamma secretase inhibitor	Mono	-
66	Immunology	Phase 2	BMS-986115		branebrutinib	Atopic dermatitis	Small molecules	gamma secretase	gamma secretase inhibitor	Mono	-
67	Immunology	Phase 2	BMS-986165		deucravacitinib	Systemic lupus erythematosus	Small molecules	TYK2	TYK2 inhibitor	Mono	-
68	Immunology	Phase 2	BMS-986165		deucravacitinib	Crohn's disease	Small molecules	TYK2	TYK2 inhibitor	Mono	-
69	Immunology	Phase 2	BMS-986165		deucravacitinib	Ulcerative colitis	Small molecules	TYK2	TYK2 inhibitor	Mono	-
70	Immunology	Phase 2	BMS-986165		deucravacitinib	Discoid lupus erythematosus	Small molecules	TYK2	TYK2 inhibitor	Mono	-
71	Immunology	Phase 2	CC-99677		MK2 inhibitor	Ankylosing spondylitis	Small molecules	MK2	MK2 inhibitor	Mono	-
72	Immunology	Phase 2	RPC4046		cendakimab	Atopic dermatitis	Antibody	IL-13	IL-13 inhibitor	Mono	Abbvie
73	Immunology	Phase 2			afimedoran	Systemic lupus erythematosus	Small molecules	TLR 7/8	TLR 7/8 inhibitor	Mono	-
74	Immunology	Phase 2			LPA1 antagonist	Pulmonary fibrosis	Small molecules	LPA1	LPA1 antagonist	Mono	-
75	Immunology	Phase 1			Anti-CD40	Autoimmune disease	Antibody	CD40	N/A	Mono	-
76	Immunology	Phase 1			IL2-CD25	Autoimmune disease	Antibody	IL2, CD25	N/A	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
77	Immunology	Phase 1			NME	Fibrosis	N/A	N/A	N/A	Mono	-
78	Immunology	Phase 1			TYK2 inhibitor	Autoimmune disease	Small molecules	TYK2	TYK2 inhibitor	Mono	-
79	Immunology	Phase 1			TYK2 inhibitor	Cutaneous lupus erythematosus	Small molecules	TYK2	TYK2 inhibitor	Mono	-
80	Infectious	Phase 2		Orencia	abatacept	COVID-19	Protein	CD80, CD86	CD80, CD86 inhibitor	Mono	-
81	Metabolic	Phase 2	BMS-986263		HSP47	Non-alcoholic steatohepatitis (NASH)	RNA	HSP47	siRNA	Mono	-
82	Neuroscience	Phase 1	CC-97489		FAAH/MGLL dual inhibitor	Neuroscience	Small molecules	FAAH, MGLL	FAAH, MGLL inhibitor	Mono	-
83	Neuroscience	Phase 1			Anti-Tau	Neuroscience	Antibody	Tau	N/A	Mono	Prothena
84	Neuroscience	Phase 1			BTK inhibitor	Neuroscience	Small molecules	BTK	BTK inhibitor	Mono	-
85	Neuroscience	Phase 1			eIF2b activator	Neuroscience	Small molecules	eIF2b	eIF2b activator	Mono	-
86	Oncology	Phase 3	BMS-936558	Opdivo	nivolumab	NSCLC, neoadjuvant	Antibody	PD-1	PD-1 antagonist	Mono	Ono
87	Oncology	Phase 3	BMS-936558	Opdivo	nivolumab	NSCLC, unresectable	Antibody	PD-1	PD-1 antagonist	Mono	Ono
88	Oncology	Phase 3	BMS-936558	Opdivo	nivolumab	NSCLC, peri-adjuvant	Antibody	PD-1	PD-1 antagonist	Mono	Ono
89	Oncology	Phase 3	BMS-936558	Opdivo	nivolumab	Head&neck squamous cell carcinoma, locally advanced, 1L	Antibody	PD-1	PD-1 antagonist	Mono	Ono

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
90	Oncology	Phase 3	BMS-936558	Opdivo	nivolumab	Esophageal cancer, 1L	Antibody	PD-1	PD-1 antagonist	Mono	Ono
91	Oncology	Phase 3	BMS-936558	Opdivo	nivolumab	Hepatocellular carcinoma, adjuvant	Antibody	PD-1	PD-1 antagonist	Mono	Ono
92	Oncology	Phase 3	BMS-936558	Opdivo	nivolumab	Hepatocellular carcinoma, 1L	Antibody	PD-1	PD-1 antagonist	Mono	Ono
93	Oncology	Phase 3	BMS-936558	Opdivo	nivolumab	non-muscle invasive bladder cancer, high-risk	Antibody	PD-1	PD-1 antagonist	Mono	Ono
94	Oncology	Phase 3	BMS-936558	Opdivo	nivolumab	Renal cell carcinoma, adjuvant	Antibody	PD-1	PD-1 antagonist	Mono	Ono
95	Oncology	Phase 3	BMS-936558	Opdivo	nivolumab	Gastric cancer, adjuvant	Antibody	PD-1	PD-1 antagonist	Mono	Ono
96	Oncology	Phase 3	BMS-936558	Opdivo	nivolumab	Adjuvant melanoma	Antibody	PD-1	PD-1 antagonist	Mono	Ono
97	Oncology	Phase 3	BMS-936558	Opdivo	nivolumab	Solid tumors, metastatic castration-resistant	Antibody	PD-1	PD-1 antagonist	Mono	Ono
98	Oncology	Phase 3	BMS-986016	Opdualag	nivolumab+ relatlimab	Adjuvant melanoma	Antibody	PD-1, LAG3	PD-1 antagonist, LAG inhibitor	Mono	Ono
99	Oncology	Phase 3	BMS-986016	Opdualag	nivolumab+ relatlimab	Colorectal cancer, 2L	Antibody	PD-1, LAG3	PD-1 antagonist, LAG inhibitor	Mono	Ono
100	Oncology	Phase 3		Opdivo(SC)+rHuPH20	nivolumab(S C)+rHuPH20	Renal cell carcinoma, advanced	Antibody	PD-1	PD-1 antagonist	Combination	Ono, Halozyme
101	Oncology	Phase 3		Opdivo(SC)+rHuPH20	nivolumab(S C)+rHuPH20	Adjuvant melanoma	Antibody	PD-1	PD-1 antagonist	Combination	Ono, Halozyme
102	Oncology	Phase 3		Opdivo+ Yervoy	nivolumab+ Ipilimumab	NSCLC, EGFR mutant	Antibody	PD-1;CLTA-4	PD-1 antagonist; CTLA4 antagonist	Combination	Ono

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
103	Oncology	Phase 3		Opdivo+ Yervoy	nivolumab+ ipilimumab	NSCLC, unresectable	Antibody	PD-1;CLTA-4	PD-1 antagonist; CTLA4 antagonist	Combination	Ono
104	Oncology	Phase 3		Opdivo+ Yervoy	nivolumab+ ipilimumab	Esophageal cancer, 1L	Antibody	PD-1;CLTA-4	PD-1 antagonist; CTLA4 antagonist	Combination	Ono
105	Oncology	Phase 3		Opdivo+ Yervoy	nivolumab+ ipilimumab	Bladder cancer, 1L	Antibody	PD-1;CLTA-4	PD-1 antagonist; CTLA4 antagonist	Combination	Ono
106	Oncology	Phase 3		Opdivo+ Yervoy	nivolumab+ ipilimumab	Renal cell carcinoma, adjuvant	Antibody	PD-1;CLTA-4	PD-1 antagonist; CTLA4 antagonist	Combination	Ono
107	Oncology	Phase 3		Opdivo+ Yervoy	nivolumab+ ipilimumab	Gastric cancer, 1L	Antibody	PD-1;CLTA-4	PD-1 antagonist; CTLA4 antagonist	Combination	Ono
108	Oncology	Phase 3		Opdivo+ Yervoy	nivolumab+ ipilimumab	Adjuvant melanoma	Antibody	PD-1;CLTA-4	PD-1 antagonist; CTLA4 antagonist	Combination	Ono
109	Oncology	Phase 3		Opdivo+ Yervoy	nivolumab+ ipilimumab	Colorectal cancer, 1L	Antibody	PD-1;CLTA-4	PD-1 antagonist; CTLA4 antagonist	Combination	Ono
110	Oncology	Phase 3		Opdivo+ Yervoy+ Cabometriq	nivolumab+ ipilimumab+ cabozantinib	Renal cell carcinoma, metastatic	Antibody	PD-1;CLTA-4;c-MET, AXL, RET	PD-1 antagonist; CTLA 4 antagonist;c-MET, A XL, RET inhibitor	Combination	Ono, Exelixis
111	Oncology	Phase 2	BMS-936558	Opdivo	nivolumab	Colorectal cancer, 1L	Antibody	PD-1	PD-1 antagonist	Mono	Ono
112	Oncology	Phase 2	BMS-936558	Opdivo	nivolumab	Pan-tumor, TMB high	Antibody	PD-1	PD-1 antagonist	Mono	Ono
113	Oncology	Phase 2	BMS-936558	Opdivo	nivolumab	Solid tumors, pediatrics	Antibody	PD-1	PD-1 antagonist	Mono	Ono
114	Oncology	Phase 2	BMS-936558	Opdivo	nivolumab	Solid tumors	Antibody	PD-1	PD-1 antagonist	Mono	Ono

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
115	Oncology	Phase 2	BMS-986016	Opdualag	nivolumab+ relatlimab	Solid tumors	Antibody	PD-1, LAG3	PD-1 antagonist, LAG inhibitor	Mono	Ono
116	Oncology	Phase 2	BMS-986218		Anti-CTLA-4 NF	Solid tumors	Antibody	CLTA-4	Cytotoxic to cells expressing CLTA-4 antagonist	Mono	-
117	Oncology	Phase 2	CC-90010			Solid tumors	Small molecules	BET	BET inhibitor	Mono	-
118	Oncology	Phase 2			Anti-CTLA-4 Probody	Solid tumors	Antibody	CLTA-4	N/A	Mono	-
119	Oncology	Phase 2			Anti-Fucosyl GM1	Solid tumors	Antibody	Fucosylated GM1 ganglioside	N/A	Mono	-
120	Oncology	Phase 2			Anti-TIGIT	Solid tumors	Antibody	TIGIT	N/A	Mono	-
121	Oncology	Phase 2			farletuzumab ecteribulin	Solid tumors	ADC	FOLR	Cytotoxic to cells expressing FOLR	Mono	Eisai
122	Oncology	Phase 2		Opdivo+CDK 4/6 inhibitor	nivolumab_CD K4/6 inhibitor	Breast cancer, neoadjuvant, ER+/HER2-	Antibody	PD-1; CDK4/6	PD-1 antagonist; CDK4/6 inhibitor	Combination	Ono
123	Oncology	Phase 2		Opdivo+ Yervoy	nivolumab+ Ipilimumab	Solid tumors	Antibody	PD-1;CLTA-4	PD-1 antagonist; CTLA4 antagonist	Combination	Ono
124	Oncology	Phase 2		Opdivo+ Yervoy	nivolumab+ Ipilimumab	Prostate cancer, metastatic castration-resistnat	Antibody	PD-1;CLTA-4	PD-1 antagonist; CTLA4 antagonist	Combination	Ono
125	Oncology	Phase 2		Pomalyst	pomalidomide	Gioblastoma, pediatrics	Small molecules	CRBN	CRBN activator	Mono	-
126	Oncology	Phase 1	BMS-90011		LSD1 inhibitor	Solid tumors	Small molecules	LSD1	LSD1 inhibitor	Mono	-

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
127	Oncology	Phase 1	BMS-936558	Opdivo	nivolumab	Solid tumors	Antibody	PD-1	PD-1 antagonist	Mono	-
128	Oncology	Phase 1	BMS-986016	Opdualag	nivolumab+ relatlimab	Solid tumors	Antibody	PD-1, LAG3	PD-1 antagonist, LAG inhibitor	Mono	Ono
129	Oncology	Phase 1	IK-175		AHR antagonist	Solid tumors	Small molecules	AHR	AHR antagonist	Mono	Ikena
130	Oncology	Phase 1			Anti-CCR8	Solid tumors	Antibody	CCR8	N/A	Mono	-
131	Oncology	Phase 1			Anti-CTLA-4 Probody	Solid tumors	Antibody	CLTA-4	N/A	Mono	-
132	Oncology	Phase 1			Anti-IL-8	Solid tumors	Antibody	IL-8	N/A	Mono	-
133	Oncology	Phase 1			Anti-ILT4	Solid tumors	Antibody	ILT4	N/A	Mono	-
134	Oncology	Phase 1			Anti-NKG2A	Solid tumors	Antibody	NKG2A	N/A	Mono	-
135	Oncology	Phase 1			Anti-SIRPα	Solid tumors	Antibody	SIRPα	N/A	Mono	-
136	Oncology	Phase 1			AR_LDD	Solid tumors	Small molecules	N/A	N/A	Mono	-
137	Oncology	Phase 1			CD3xPSCA Bispecific	Solid tumors	Antibody	CD3, PSCA	Bispecific antibody (CD3, PSCA)	Mono	Avencell
138	Oncology	Phase 1			DGK inhibitor	Solid tumors	Antibody	DGK	DGK inhibitor	Mono	-
139	Oncology	Phase 1			IL-12 Fc	Solid tumors	Antibody	IL-12	N/A	Mono	-
140	Oncology	Phase 1			MAGE A4/8 TCE	Solid tumors	Antibody	MAGE A4/8	T-cell engager	Mono	

No.	질환분야	개발단계	코드	제품명	성분명	적응증	물질	타겟	작용기전	단독/병용	파트너
141	Oncology	Phase 1			STING agonist	Solid tumors	Small molecules	STING	STING agonist	Mono	-
142	Oncology	Phase 1			TGFβ inhibitor	Solid tumors	Antibody	TGFβ	TGFβ inhibitor	Mono	-
143	Oncology	Phase 1			TIGIT Bispecific	Solid tumors	Antibody	TIGIT	Bispecific antibody (TIGIT)	Mono	Agenus